[Current status of treatment for HBV-related cirrhosis].
Ikeda
Kenji
K
Department of Gastroenterology, Toranomon Hospital.
D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D004279:DNA, Viral / Q000097:blood; D006509:Hepatitis B; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D016899:Interferon-beta / Q000008:administration & dosage* / Q000009:adverse effects; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000628:therapy* / Q000821:virology*; D008113:Liver Neoplasms / Q000517:prevention & control / Q000821:virology; D016031:Liver Transplantation; D012306:Risk; D016896:Treatment Outcome
D000998:Antiviral Agents; D015415:Biomarkers; D004279:DNA, Viral; D007136:Immunoglobulins; D016898:Interferon-alpha; D019259:Lamivudine; D016899:Interferon-beta; D000410:Alanine Transaminase; C045213:hepatitis B hyperimmune globulin